Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase (Q24305651)

GOA release 2020-03-11

bile acid binding

1 reference

GOA release 2020-03-11

author name string

Jennifer L Ekstrom

1

0 references

Thomas A Pauly

2

0 references

Maynard D Carty

3

0 references

Walter C Soeller

4

0 references

Jeff Culp

5

0 references

Dennis E Danley

6

0 references

Dennis J Hoover

7

0 references

Judith L Treadway

8

0 references

E Michael Gibbs

9

0 references

Robert J Fletterick

10

0 references

Yasmina S N Day

11

0 references

David G Myszka

12

0 references

Virginia L Rath

Pharmacologic therapy for type 2 diabetes mellitus

13

0 references

language of work or name

English

0 references

publication date

August 2002

0 references

published in

Chemistry and Biology

0 references

volume

9

0 references

issue

8

0 references

page(s)

915-24

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Allosteric drugs: thinking outside the active-site box.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Allosteric inhibition of glycogen phosphorylaseaby the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: the role of the water structure and its contribution to binding

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Human liver glycogen phosphorylase inhibitors bind at a new allosteric site

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

A new allosteric site in glycogen phosphorylase b as a target for drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Kinetic analysis of a protein antigen-antibody interaction limited by mass transport on an optical biosensor

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Kinetic mechanism of phosphorylase a. I. Initial velocity studies

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Conformational Changes in Glycogen Phosphorylase Studied with a Spin-Label Probe

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

N-acetyl-beta-D-glucopyranosylamine: a potent T-state inhibitor of glycogen phosphorylase. A comparison with alpha-D-glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Processing of X-ray diffraction data collected in oscillation mode

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Improved methods for building protein models in electron density maps and the location of errors in these models

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Improving biosensor analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021

Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2802%2900186-2

7 January 2021